ENTX (Entera Bio) Cyclically Adjusted PB Ratio: (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENTX Entera Bio Ltd ENTX
23 GF Score
Price $1.99
! 3 Warning Signs
View Full Analysis

What is Entera Bio Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Entera Bio  (NAS:ENTX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Entera Bio Cyclically Adjusted PB Ratio Related Terms


Entera Bio Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Entera Bio's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio Cyclically Adjusted PB Ratio Chart

Entera Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entera Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ENTX vs HRTX, OKYO, EDSA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Entera Bio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entera Bio Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Entera Bio's Cyclically Adjusted PB Ratio falls into.


ENTX
23GF Score
Entera Bio Ltd ENTX
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Entera Bio's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Entera Bio's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.229/330.2130*330.2130
=0.229

Current CPI (Mar. 2026) = 330.2130.

Entera Bio Quarterly Data

Book Value per Share CPI Adj_Book
201512 -2.248 236.525 -3.138
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 -2.209 241.432 -3.021
201706 -2.342 244.955 -3.157
201709 -2.506 246.819 -3.353
201712 -2.761 246.524 -3.698
201803 0.000 249.554 0.000
201806 -2.936 251.989 -3.847
201809 1.090 252.439 1.426
201812 0.883 251.233 1.161
201903 0.669 254.202 0.869
201906 0.544 256.143 0.701
201909 0.332 256.759 0.427
201912 0.667 256.974 0.857
202003 0.549 258.115 0.702
202006 0.396 257.797 0.507
202009 0.313 260.280 0.397
202012 0.357 260.474 0.453
202103 0.320 264.877 0.399
202106 0.895 271.696 1.088
202109 0.903 274.310 1.087
202112 0.783 278.802 0.927
202203 0.685 287.504 0.787
202206 0.599 296.311 0.668
202209 0.497 296.808 0.553
202212 0.408 296.797 0.454
202303 0.350 301.836 0.383
202306 0.286 305.109 0.310
202309 0.216 307.789 0.232
202312 0.293 306.746 0.315
202403 0.249 312.332 0.263
202406 0.235 314.175 0.247
202409 0.177 315.301 0.185
202412 0.208 315.605 0.218
202503 0.427 319.799 0.441
202506 0.380 322.561 0.389
202509 0.334 324.800 0.340
202512 0.284 324.054 0.289
202603 0.229 330.213 0.229

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Entera Bio Business Description

Other Exchanges 5DT:Germany
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
23GF Score

Get the complete analysis for ENTX

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price